Ventripoint Diagnostics Ltd., a medical device company, develops and commercializes diagnostic tools that monitor patients with heart disease primarily in Canada, the Unites States, and China.
The last earnings update was 145 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
In this section, we usually try to help investors determine whether VentriPoint Diagnostics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as VentriPoint Diagnostics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.
Show me the analysis anyway
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
VentriPoint Diagnostics. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
VentriPoint Diagnostics's earnings available for a low price, and how does
this compare to other companies in the same industry?
VentriPoint Diagnostics has negative assets, we can't compare the value of its assets to the DE Medical Equipment industry average.
Take a look at our analysis of 5V7’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through VentriPoint Diagnostics's regulatory filings and announcements.
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as VentriPoint Diagnostics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Medical Equipment industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare VentriPoint Diagnostics's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare VentriPoint Diagnostics's earnings growth to the Germany market average as no estimate data is available.
Unable to compare VentriPoint Diagnostics's revenue growth to the Germany market average as no estimate data is available.
Unable to determine if VentriPoint Diagnostics is high growth as no earnings estimate data is available.
Unable to determine if VentriPoint Diagnostics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
VentriPoint Diagnostics's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
VentriPoint Diagnostics's finances.
The net worth of a company is the difference between its assets and liabilities.
VentriPoint Diagnostics's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
VentriPoint Diagnostics has no long term commitments.
This treemap shows a more detailed breakdown of
VentriPoint Diagnostics's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
VentriPoint Diagnostics has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. George Adams, B.A.Sc., M.A.Sc., Ph.D., ICD.D., has been the Chief Executive Officer of VentriPoint Diagnostics Ltd. since October 1, 2010 and served as its President from October 1, 2010 to December 2017. Dr. Adams has been the President of Hemo-Stat Ltd since 1989. He is a Director of Cell MedX Corp. since March 2018. He served as the President and Chief Executive Officer of Amorfix Life Sciences Ltd. from April 1, 2005 to June 3, 2010 and as an Executive Director from September 24, 2005 to June 3, 2010. Dr. Adams served as President and Chief Executive Officer of the University of Toronto Innovations Foundation from 1999 to October 2004, where he was involved in creating companies and commercializing technologies. He served as President of the Canadian Biomaterials Society and Corvits. He served as the President of Corvita from 1994 to 1996. He served as a Senior Scientist of the Canadian Red Cross Blood Transfusion Service until 1980. Dr. Adams served as an Associate Professor of Biochemistry and Surgery at University of Ottawa. He served as the Chairman of Sernova Corp. from May 3, 2007 to March 2015. Dr. Adams has also been a Director of 8 start-up companies. He has been a Director of VentriPoint Diagnostics Ltd. since October 1, 2010. He serves as a Member of Advisory Board of Roadmap Capital Inc. He served as Director of Sernova Corp. until April 28, 2015 and previously also served as its Director since September 25, 2006. Dr. Adams served as Director of Artificial Heart Development Program. He served as a Member of Scientific Advisory Board at Resverlogix Corp. since May 2006. Dr. Adams is an expert in thrombosis and Vascular biology, has partnered with Baxter Heathcare, World Heart, Dupont, Corvita, Pfizer and Boston Scientific over 30 years to develop and commercialize medical devices. He has 124 publications including 9 invited reviews, 26 full papers and 3 patents. Dr. Adams is a reviewer for numerous scientific journals, national granting agencies and several national and provincial Centers of Excellence. He has an extensive history of combining science and entrepreneurial ventures. Dr. Adams obtained his PhD. in Medical Sciences from McMaster University. He received his B.A.S.C and an M.A.S.C. in Mechanical Engineering from the University of Waterloo. Dr. Adams has a postdoctoral year in Vascular Biology at the Bayor College of Medicine.
George's compensation has increased whilst company is loss making.
George's remuneration is about average for companies of similar size in Germany.
Management Team Tenure
Average tenure of the
management team in years:
The average tenure for the VentriPoint Diagnostics management team is less than 2 years, this suggests a new team.
CEO & Director
CFO & Corporate Secretary
Vice President of Development & Operations
Application Specialist & Chief Trainer
Board of Directors Tenure
Average tenure of the
board of directors in years:
The tenure for the VentriPoint Diagnostics board of directors is about average.
Ventripoint Diagnostics Ltd., a medical device company, develops and commercializes diagnostic tools that monitor patients with heart disease primarily in Canada, the Unites States, and China. The company offers Ventripoint Medical System, medical imaging system that is used to generate three-dimensional models with critical volume and functional measurements of a patient’s heart chambers. It also provides a suite of applications for various heart diseases and imaging modalities, including congenital heart diseases, left or right heart failure, and normal hearts. The company was incorporated in 2005 and is headquartered in Toronto, Canada.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.